drugset / Trial / NCT00396214
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
Phase 3
Terminated
83 enrolled
Solvay Pharmaceuticals
H. Lundbeck A/S · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
Timeline
- Start
- 2007-04
- Primary completion
- 2008-01
- Completion
- 2008-01
Outcome
Outcome not reported
Stopped: “This trial discontinued on 2 May 2008 due to lack of enrolment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bifeprunox | Small molecule | 30 mg | Oral |
| Comparator | Quetiapine | Small molecule | 400 mg | Oral |